Silymarin in NAFLD

• Status: Withdrawn
• Trial end date: 2021-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the influence of Silymarin in reducing laboratory, ultrasonographic (Fibroscan) and metabolic components of NAFLD. Half of the patients will receive Silymarin (Verum) while the other half will receive placebo

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Rijeka
• Collaborators: Belupo; Belupo d.o.o., Koprivnica, Croatia; University of Rijeka, Faculty of Health studies; University of Rijeka, Medical Faculty
• Treatments: Silymarin

Criteria

Inclusion Criteria:

• NAFLD patients

• signed informed consent

• possibility to follow instruction and the protocol

Exclusion Criteria:

• chronic B or C hepatitis

• usage of hepatotoxic drugs in the period of 6 months before inclusion

• chronic kidney insufficiency (grade 4 and 5), hemodialysis

• any other chronic liver disease

• opioid dependancy

• any malignancy

• HIV seropositivity

• alcohol abuse

• pregnancy

• inability to follow the protocol